ArticleNutrition & diabetes2024
Assessing the economic impact of obesity and overweight on employers: identifying opportunities to improve work force health and well-being.
Article in Nutrition & diabetes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Robotic-Assisted Single Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy - A Systematic Review.Obesity surgery · 2026Pooled it
- Employee perceptions and experiences with tirzepatide treatment for obesity or overweight in the US: Insights from the PERCEPTIONS Survey.Obesity pillars · 2026Article
- Functional Annotation of GWAS Loci Using Public Transcriptome and Epigenome Datasets Reveals Non-Coding Genes and Regulatory Elements Which May Contribute to BMI.International journal of molecular sciences · 2026Article
- A Longitudinal Cohort Study of the Costs of Adolescent Obesity Into Young Adulthood.Obesity science & practice · 2026Article
- Advancing Lost Productivity Measurement in Economic Evaluations: Evidence Priorities from a Targeted Literature Review and Expert Workshop.PharmacoEconomics - open · 2026Review
- Does Weight Loss Translate to Workplace Gains? Results of an Employment Questionnaire in Adults With Prediabetes and Overweight or Obesity.Diabetes, obesity & metabolism · 2026Article
- Obesity Pharmacotherapy: An Urgent Need for Progressing Science, Access, and Equity-JACC: Advances Expert Panel.JACC. Advances · 2026Review
- Negative Consequences of Removing GLP-1 RA Obesity Coverage: A Cross-Sectional Cohort Comparison Study.Obesity science & practice · 2026Article
- The Influence of BMI on Mortality and Clinical Outcomes After Burns.European burn journal · 2026Article
- Employee retention for subscribers with and without an obesity diagnosis in self-insured employer health plans: A claims-based analysis.Journal of managed care & specialty pharmacy · 2026Observational
- Development of a Follow-Up Protocol for Patients Treated with Injectable Semaglutide for Weight Loss: Design of a Research Study in Community Pharmacy.Farmaceuticos comunitarios · 2026Article
- Review
- Associations of nutrition knowledge and dietary habits with stress among university employees in Saudi Arabia: mixed-methods evidence.Frontiers in nutrition · 2026Article
- Article
- Application of nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions.Obesity pillars · 2025Review
- Understanding the clinical characteristics associated with health care costs and cost savings upon weight reduction in individuals with obesity or overweight.Diabetes, obesity & metabolism · 2025Article
- Prolonged exposure to food odors suppresses feeding via an olfactory bulb-to-hypothalamus circuit.Nature communications · 2025Article
- Prevalence of obesity among adults in Otjomuise Community in Namibia.Health SA = SA Gesondheid · 2025Article
- Assessing the economic impact of obesity and overweight on employers: identifying opportunities to improve work force health and well-being.Nutrition & diabetes · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesObesity is a major public health issue, significantly affecting national and individual health and economic well-being. This study quantifies the economic impact of excess body weight on employers and employees in 2023, offering insights for obesity prevention and treatment.
methodsWe utilized data from the National Health Interview Survey, National Health and Nutrition Examination Survey, Medical Expenditure Panel Survey, and Current Population Survey. Published reports and original estimates were combined to assess the economic burden for the U.S. and across seven major industries (Construction, Education & Health, Financial Activities, Government, Manufacturing, Professional & Business Services, and Transportation & Utilities). We compared the economic outcomes for adults with obesity and overweight to those with healthy weight, focusing on direct and indirect costs. Potential savings from different weight loss scenarios were estimated using the Disease Prevention & Treatment Microsimulation Model.
resultsIn 2023, among 158 million civilian employees on nonfarm payrolls, 30% had obesity and 34% had overweight, resulting in a combined economic burden of $425.5 billion (obesity: $347.5 billion; overweight: $78 billion). This includes excess medical costs of obesity ($115 billion), presenteeism (obesity: $113.8 billion; overweight: $46.5 billion), absenteeism from obesity ($82.3 billion), excess medical costs of overweight ($31.5 billion), obesity-related disability payments ($31.1 billion), and workers' compensation payments ($5.2 billion). For a hypothetical firm with 10,000 employees (plus dependents), the annual costs were $22 million for obesity and $4.9 million for overweight, with average costs of $6472 per employee with obesity, $1244 per employee with overweight, $1514 per adult dependent with obesity, and $380 per adult dependent with overweight. Medical savings over 5 years range from $153.3 billion with a 5% weight loss to $326.1 billion with 25% weight loss at the industry level.
conclusionThe substantial economic costs imposed by obesity and overweight on employers and employees highlight the need for resources dedicated to treatment and prevention, which can result in reduced medical expenses and improved productivity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.